ISRG · Intuitive Surgical
AI read · Good for ISRG
The AI's read
That growth came from more procedures and system placements, not just one part of the business. Growth across da Vinci and Ion, plus adoption of da Vinci 5 and SP, points to demand across several products. The company plans to lower instrument and accessory sales per procedure to encourage more high-volume benign procedures. That could mean less sales from each case. It also plans significant spending on overseas markets and new technology. The call reported a no-fault lawsuit settlement tied to third-party servicing but gave no cost. These facts temper the growth story, but do not outweigh the growth reported across the business.